Lipid lowering drugs dr najeeb immunology

Non-Statin Lipid Lowering Agents

This table provides an overview of various non-statin lipid-lowering agents, summarizing their mechanisms, lipid-lowering efficacy, impact on major adverse cardiovascular events (MACE), advantages, and disadvantages.

Drug Classes Covered:

• Bempedoic Acid
• Inclisiran
• PCSK9 Inhibitors (Evolocumab, Alirocumab)
• Ezetimibe
• Bile Acid Sequestrants
• Niacin
• Fibrates
• Omega-3 Fatty Acids (EPA)

Each agent shows unique attributes in lipid lowering, cardiovascular impact, and side effect profiles.

Notably:

• PCSK9 inhibitors and Inclisiran provide substantial LDL-C reduction.
• Fibrates and Omega-3 fatty acids show greater triglyceride reduction benefits, useful in hypertriglyceridemia.
• Bempedoic Acid and Ezetimibe offer alternatives to statins, especially for those with statin-associated muscle symptoms.

Produced by: Dr.

Natalie Marreromed
Reviewed by: Dr. Patrick Zakka

CardioNerds Infographics

Explore our comprehensive colle